Epidemiological and overall survival characteristics of breast cancer patients in Ege University Hospital database
Abstract
Aim: The study aimed to define the baseline characteristics, treatment modalities and survival outcome of breast cancer patients who admitted to Ege University School of Medicine between 1992-2017.
Materials and Methods: The breast cancer patients’ data that was collected by Ege University Cancer Research Center, was recorded to CANREG computer program, and analyses was performed according to WHO and SEER system definitions. Chi-square, General Linear Model and Kaplan-Meier survival analyses was performed for further analyses. Log Rank (Mantel-Cox), Breslow (Generalized Wilcoxon) and Tarone-Ware statistics was used for survival analyses. p<0.05 was considered as statistically significant.
Results: The 13079 breast cancer patients’ data was analyzed. 98.7% of the patients were female and 1.3% was male in gender. The most common age interval in diagnosis was 40-49 years in women and 60-69 years in men. The female patients initial age at diagnosis was younger than male patients. The most common localization of the primary tumor was upper-outer quadrant (46%) and the most common histology was detected as invasive ductal carcinoma (57.3%). Nearly half of breast cancer patients were diagnosed in locally advanced setting. The denovo metastatic disease frequency was 17.7% in women and 8.4% in men. The 5- and 10-year overall survival in female and male patients was 94.1% and 86.6% in localized disease, 85.5% and 71.1% in locally advanced setting and 39.1% and 22.7% in metastatic setting respectively. When all stage groups were analyzed together, the 5- and 10-year survival was found 85.4% and 77.4% in women and 74.3% and 63% in men.
Conclusion: The data that is presented in this article is the largest dataset that has been reported in Turkey. Breast cancer is composed of 1 of 4 all-female cancers in our dataset. The female patients are diagnosed in earlier ages than men and demonstrate better prognosis.
References
- Bray F, Ferlay J, Soerjomataram I and et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Cancer J Clin. 2018; 68: 394-424.
- Héry C, Ferlay J, Boniol M, Autier P. Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 coun- tries with Caucasian majority populations. Ann Oncol 2008; 19 (6): 1187-94.
- Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007 Apr 19; 356 (16): 1670-4.
- Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001; 2 (3): 133-40.
- Haydaroğlu A, Dubova S, Ozsaran Z, Bolukbaşı Y, et al. Ege Üniversitesinde Meme Kanserleri: 3897 Olgunun Değerlendirilmesi. Meme Sağlığı Dergisi 2005; 1 (1): 6-11.
- Abdelwahab Yousef AJ. Male Breast Cancer: Epidemiology and Risk Factors. Semin Oncol. 2017 Aug;44(4):267-72.
- Çakar B, Sert F, Gürsoy P, Emekdaş B, Özsaran Z, Gökmen E, Haydaroğlu A. Long-Term Follow-Up of Patients with Male Breast Cancer, Single-Center Experience. Turk J Oncol 2019; 34 (2): 66–71.
- Li CI. Risk of mortality by histologic type of breast cancer in the United States. Horm Cancer. 2010 Jun;1 (3): 156-65.
- Chen MT, Sun HF, Zhao Y et al. Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: a SEER population-based analysis. Sci Rep. 2017 Aug 23; 7 (1): 9254.
Ege Üniversitesi Hastanesi veri tabanında meme kanseri hastalarının epidemiyolojisi ve genel sağ kalım özellikleri
Abstract
Amaç: Ege Üniversitesi Hastanesinde 1992-2017 arası kanser tanı ve tedavisi yapılan 13079 meme kanser tanılı hastanın genel özellikleri, tedavi modaliteleri ve sağ kalım sürelerinin tanımlanması amaçlanmıştır.
Gereç ve Yöntem: Ege Üniversitesi Kanserle Savaş Araştırma ve Uygulama Merkezi tarafından toplanan meme kanseri verileri CANREG özel bilgisayar programına kayıt edilmiş, DSÖ ve SEER sistemleri temelinde gruplanarak analizler yapılmıştır. İstatistik analizlerde Ki-kare, General Linear Model, Kaplan Meier sağ kalım analizleri uygulanmıştır. Kaplan Meier Sağ kalım analizinde Log Rank (Mantel-Cox), Breslow (Generalized Wilcoxon) ve Tarone-Ware istatistikleri kullanılmıştır. İstatistik analizlerde p<0,05 istatistiksel olarak anlamlı kabul edilmiştir
Bulgular: 13079 meme kanser tanılı hasta verisi analiz edilmiştir. Meme kanseri(MK) olgularımızın %98,7’si kadın, %1,3’ü erkektir. Olgularımızın en sık görüldüğü yaşlar kadınlarda 40-49 yaşlarda, erkeklerde ise 60-69 yaş aralığındadır. Kadın olgularımızda tanı anındaki görülme yaşları erkek olgulara göre daha genç yaşlardadır. Meme kanserli olgularımızda en sık yerleşim üst-dış kadranda (%46), en sık histolojik alt tip invaziv duktal kanser (%57,3) olarak izlenmiştir. Hastaların yaklaşık yarısı lokal ileri dönemde tanı almaktadır. Denovo metastatik hastalık erkeklerde %17,7 iken kadınlarda bu oran %8,4 dür. Evrelere göre beş ve 10 yıllık GSK sırasıyla; Lokalize kanserlerde %94,1 ve %86,6, Lokal ileri evrede ise %85,5 ve %71,1, metastatik dönemde ise %39,1 ve %22,7’dir. Tüm evreler birlikte değerlendirildiğinde kadınlarda 5 ve 10 yıllık sağ kalımlar %85,4 ve %77,4 iken erkeklerde bu oranlar %74,3 ve %63’e düşmektedir.
Sonuç: EÜ Hastane Tabanlı Kanser Kayıt sisteminde kadın kanserlerinin dörtte birini meme kanserleri oluşturmaktadır. Bizim 13079 olgu içeren serimiz tek merkez olarak Türkiye’deki en geniş meme kanseri serisidir. Kadın olgularımızda meme kanseri erkek cinsiyete göre daha erken yaşta izlenmektedir ve daha iyi sağ kalımla ilişkilidir.
References
- Bray F, Ferlay J, Soerjomataram I and et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Cancer J Clin. 2018; 68: 394-424.
- Héry C, Ferlay J, Boniol M, Autier P. Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 coun- tries with Caucasian majority populations. Ann Oncol 2008; 19 (6): 1187-94.
- Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007 Apr 19; 356 (16): 1670-4.
- Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001; 2 (3): 133-40.
- Haydaroğlu A, Dubova S, Ozsaran Z, Bolukbaşı Y, et al. Ege Üniversitesinde Meme Kanserleri: 3897 Olgunun Değerlendirilmesi. Meme Sağlığı Dergisi 2005; 1 (1): 6-11.
- Abdelwahab Yousef AJ. Male Breast Cancer: Epidemiology and Risk Factors. Semin Oncol. 2017 Aug;44(4):267-72.
- Çakar B, Sert F, Gürsoy P, Emekdaş B, Özsaran Z, Gökmen E, Haydaroğlu A. Long-Term Follow-Up of Patients with Male Breast Cancer, Single-Center Experience. Turk J Oncol 2019; 34 (2): 66–71.
- Li CI. Risk of mortality by histologic type of breast cancer in the United States. Horm Cancer. 2010 Jun;1 (3): 156-65.
- Chen MT, Sun HF, Zhao Y et al. Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: a SEER population-based analysis. Sci Rep. 2017 Aug 23; 7 (1): 9254.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Supplement |
| Authors | |
| Publication Date | December 31, 2019 |
| Submission Date | February 15, 2019 |
| Published in Issue | Year 2019Volume: 58 Suppl: 2 (Oncology) |
